YOLFTbeta
Cardiff Oncology Inc

Cardiff Oncology Inc

CRDF · NASDAQ · Healthcare / Biotechnology

0.73USD+0.00 (+0.33%)

Price History

Full chart

Market Stats

Previous Close0.7276
Open0.73
Day Range0.71 – 0.74
52-Week Range0.76 – 3.31
Volume205.20K
Market Cap96.47M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.59
Dividend Yield0.00%
Beta1.46
50-Day Avg1.02
200-Day Avg1.66

About

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Mani Mohindru Ph.D.
  • Employees30
  • Headquarters11055 Flintkote Avenue, San Diego, CA, United States, 92121, USA
  • Websitehttps://www.cardiffoncology.com

Leadership

  • Dr. Mani Mohindru Ph.D.President, CEO & Director · b. 1972
  • Dr. Roger Sidhu FRCPC, M.D.Chief Medical Officer · b. 1976
  • Mr. Joshua Muntner BFA, M.B.A.Chief Financial Officer · b. 1969
  • Dr. Ajay Aggarwal M.B.A., M.D.Chief Operating Officer
  • Ms. Brigitte LindsayChief Accounting Officer · b. 1969
  • Dr. Tod Smeal Ph.D.Chief Scientific Officer · b. 1965
  • Ms. Elizabeth AndersonVP of Finance & Administration

Financials

Income Statement

Currency: USD2004-12-312005-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue--650.00K265.67K257.70K450.00K259.25K280.00K313.00K381.00K505.00K378.00K244.63K366.00K359.00K386.00K488.00K683.00K593.00K
Growth (%)----59.13%-3.00%+74.62%-42.39%+8.01%+11.79%+21.73%+32.55%-25.15%-35.28%+49.61%-1.91%+7.52%+26.42%+39.96%-13.18%
Cost of Revenue-----1.92M3.48M15.00K629.00K1.73M1.81M597.00K11.16M11.23M500.00K200.00K398.00K404.00K904.00K
Gross Profit--650.00K265.67K257.70K-1.47M-3.22M265.00K-316.00K-1.35M-1.31M-219.00K244.63K366.00K359.00K386.00K488.00K683.00K593.00K
Gross Margin--100.00%100.00%100.00%-326.73%-1242.91%94.64%-100.96%-354.07%-258.61%-57.94%100.00%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense--3.04M5.64M3.23M3.38M7.47M15.21M24.96M38.80M24.29M16.83M16.92M19.45M29.21M40.29M45.90M49.33M49.55M
Operating Income-5.38M-8.00M-2.39M-5.38M-2.98M-4.85M-10.69M-14.95M-25.27M-40.15M-25.60M-17.05M-16.68M-19.09M-28.86M-39.90M-45.41M-48.65M-48.96M
Operating Margin---367.69%-2024.84%-1155.16%-1077.56%-4123.71%-5337.50%-8074.76%-10536.75%-5068.51%-4511.38%-6817.79%-5214.75%-8037.60%-10337.31%-9305.74%-7123.13%-8256.32%
EBITDA-5.38M-8.00M-2.17M-5.37M-2.10M-11.53M-11.66M-14.71M-24.89M-36.76M-22.82M-15.70M-15.92M-18.84M-27.84M-38.47M-41.04M-45.03M-44.95M
EBITDA Margin---333.64%-2021.68%-815.11%-2561.80%-4498.97%-5253.69%-7953.66%-9647.94%-4518.59%-4153.35%-6507.70%-5147.27%-7754.87%-9965.80%-8410.45%-6592.53%-7579.60%
Net Income-5.37M-7.84M-2.48M-5.45M-2.24M-11.57M-11.81M-14.32M-27.47M-39.20M-24.91M-16.46M-16.41M-19.31M-28.29M-38.70M-41.44M-45.43M-45.85M
Net Income Margin---381.54%-2051.13%-868.94%-2570.22%-4555.88%-5116.07%-8776.68%-10289.76%-4932.08%-4354.76%-6709.74%-5275.14%-7880.50%-10026.94%-8492.01%-6651.68%-7732.04%
R&D619.63K1.88M-3.69M910.68K1.92M3.95M6.67M10.59M15.01M7.88M8.16M11.16M11.23M17.38M27.11M32.86M36.85M35.33M
R&D as % of Total Revenue---1389.35%353.40%426.67%1522.72%2380.36%3384.66%3938.85%1560.99%2159.79%4562.87%3069.67%4840.11%7022.54%6732.99%5395.61%5957.67%
Interest Expense--90.00K115.58K56.64K017.00K843.00K1.53M1.38M1.03M25.41K234.17K2.00K264.00K1.58M---
Interest Expense % of Total Revenue--13.85%43.51%21.98%0.00%6.56%301.07%487.37%361.03%204.74%6.72%95.72%0.55%73.54%409.59%---

Balance Sheet

Currency: USD2004-12-312005-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-1.07M-5.56M760.00K512.22K1.04M11.66M27.16M28.90M71.45M43.95M12.29M14.17M13.09M134.73M149.54M116.19M81.64M97.19M61.88M
Total Liabilities--4.55M5.51M5.27M9.50M6.76M20.55M22.75M24.18M5.78M4.09M5.78M6.57M9.13M9.85M11.90M14.24M16.50M
Total Equity---3.79M-5.00M-4.23M2.17M20.39M8.35M48.70M19.77M6.51M10.08M7.31M128.16M140.42M106.34M69.74M82.95M45.39M
Cash-1.07M-5.56M550.00K58.70K700.37K10.82M25.84M27.29M67.49M37.89M8.23M11.45M10.20M130.98M11.94M16.35M21.66M51.47M17.47M
Total Debt--2.11M2.34M--521.16K14.95M16.47M16.54M1.33M-1.73M869.00K3.12M2.71M2.15M1.52M832.00K
Net Debt1.07M5.56M1.56M2.28M-700.37K-10.82M-25.32M-12.34M-51.02M-21.36M-6.89M-11.45M-8.47M-130.11M-8.82M-13.63M-19.51M-49.95M-16.64M

Cash Flow

Currency: USD2005-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-4.40M-1.23M-2.09M-1.93M-4.93M-7.32M-12.73M-22.12M-31.04M-23.28M-13.20M-13.27M-16.31M-23.04M-33.82M-30.89M-37.69M-37.92M
Investing Cash Flow-72.98K-10.00K-132.45K-1.53K-270.08K-649.28K-299.79K-2.23M-24.83M23.96M23.00K-67.62K-211.88K-131.45M38.15M36.20M13.73M1.34M
Financing Cash Flow5.11M1.65M1.73M2.57M15.32M22.98M14.48M64.55M2.30M-6.38M16.40M12.08M137.31M35.45M75.00K053.78M2.58M
Capital Expenditure010.00K27.75K1.53K270.08K649.28K363.29K2.24M823.00K100.00K5.10K68.00K211.88K205.00K892.00K582.00K80.00K44.00K
Free Cash Flow-4.40M-1.24M-2.12M-1.93M-5.20M-7.97M-13.09M-24.36M-31.86M-23.38M-13.21M-13.34M-16.53M-23.25M-34.71M-31.47M-37.77M-37.97M
Dividends Paid60.74K-----23.02M24.24M24.24M24.24M24.24M24.24M24.24M24.00K414.00K---
FCF to OCF100.00%100.81%101.33%100.08%105.47%108.87%102.85%110.13%102.65%100.43%100.04%100.51%101.30%100.89%102.64%101.88%100.21%100.12%
Dividend Paid to FCF-1.38%------175.81%-99.51%-76.08%-103.67%-183.57%-181.76%-146.67%-0.10%-1.19%---

Earnings

Report DateMar 31, 2010Jun 30, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Aug 29, 2012Nov 28, 2012Mar 31, 2013May 14, 2013Aug 14, 2013Nov 14, 2013Mar 17, 2014May 12, 2014Aug 7, 2014Nov 6, 2014Mar 12, 2015May 5, 2015Aug 10, 2015Nov 9, 2015Mar 10, 2016May 10, 2016Aug 4, 2016Nov 9, 2016Mar 15, 2017May 10, 2017Aug 9, 2017Nov 9, 2017Feb 26, 2018May 8, 2018Aug 3, 2018Nov 7, 2018Mar 6, 2019May 7, 2019Aug 8, 2019Nov 7, 2019Feb 27, 2020May 7, 2020Aug 11, 2020Nov 5, 2020Feb 25, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Feb 24, 2022May 5, 2022Aug 4, 2022Nov 3, 2022Mar 2, 2023May 4, 2023Aug 9, 2023Nov 2, 2023Feb 29, 2024May 2, 2024Aug 8, 2024Nov 7, 2024Feb 26, 2025May 8, 2025Jul 29, 2025Nov 6, 2025Feb 24, 2026May 14, 2026Aug 11, 2026Nov 5, 2026
EPS Estimate----------6.12-8.64-10.80-16.20-13.68-14.04-13.68-15.60-18.36-18.48-17.52-19.80-17.88-21.24-27.00-23.28-23.04-17.28-23.04-17.28-9.00-5.76-1.98-1.98-1.05-1.07-1.02-0.84-0.51-0.41-0.24-0.19-0.14-0.15-0.15-0.17-0.17-0.23-0.25-0.24-0.23-0.22-0.25-0.29-0.28-0.25-0.25-0.27-0.25-0.19-0.20-0.21-0.20-0.12-0.17-0.14
EPS Actual-4.44-6.21-3.94-4.12-0.00-9.32-7.67-20.47-3.35-7.20-5.04-24.48-18.00-3.60-12.24-12.24-16.57-18.00-17.27-20.53-17.04-18.00-26.14-24.66-24.41-22.44-19.44-9.82-8.64-4.32-6.06-1.80-1.08-1.09-1.02-0.78-0.71-0.51-0.41-0.51-0.19-0.08-0.14-0.17-0.17-0.23-0.25-0.24-0.20-0.20-0.25-0.25-0.22-0.21-0.22-0.26-0.25-0.21-0.20-0.21-0.17-0.11-0.18-0.14-
Surprise----------17.65%41.67%-126.67%-11.11%73.68%12.82%10.53%-6.22%1.96%6.55%-17.18%13.94%-0.67%-23.07%8.67%-4.85%2.60%-12.50%57.38%50.00%52.00%-5.21%9.09%45.45%-3.81%4.67%23.53%15.48%0.00%0.00%-112.50%0.00%42.86%6.67%-13.33%0.00%-35.29%-8.70%4.00%16.67%13.04%-13.64%0.00%24.14%25.00%12.00%-4.00%7.41%15.15%-5.26%-5.00%19.05%45.00%-50.00%17.65%-
Timing----------After-hoursAfter-hoursAfter-hours-After-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hours-

Key Statistics & Ratios

Market Cap96.47M
Enterprise Value69.40M
Trailing P/E0.00
Forward P/E0.00
Price / Sales189.89
Price / Book3.90
EPS-0.59
Book Value0.387
Revenue (TTM)508.00K
Gross Profit (TTM)-34.82M
EBITDA-41.91M
Profit Margin0.00%
Operating Margin-9245.19%
Return on Equity-94.09%
Return on Assets-46.73%
Shares Outstanding77.80M
Shares Float75.38M
Beta1.46
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Strong Buy
Based on 7 analystsTarget 5.81
  • Strong Buy
    5
  • Buy
    2

Ownership Breakdown

Institutions
21.24%
Insiders
6.20%
Retail / Other
72.56%

Top Institutional Holders

  • BlackRock Inc
    3.98M5.12%
  • Vanguard Capital Management, LLC
    2.86M3.67%
  • LAURION CAPITAL MANAGEMENT LP
    2.65M3.40%
  • Pfizer Inc
    2.41M3.10%
  • Geode Capital Management, LLC
    1.60M2.06%
  • Franklin Templeton Inc
    1.21M1.55%
  • State Street Corp
    1.19M1.53%
  • Blair William & Co
    912.51K1.17%
  • F.L.Putnam Investment Management
    595.13K0.77%
  • Northern Trust Corp
    493.20K0.63%
  • Vanguard Fiduciary Trust Co
    446.23K0.57%
  • Vanguard Portfolio Management, LLC
    437.21K0.56%
  • UBS Group AG
    400.58K0.51%
  • Bank of New York Mellon Corp
    303.43K0.39%
  • XTX Topco Ltd
    250.22K0.32%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    2.07M2.66%
  • Franklin Biotechnology Discv A(acc)USD
    766.68K0.99%
  • Franklin Biotechnology Discovery A
    438.96K0.56%
  • Fidelity Extended Market Index
    353.99K0.46%
  • Abante Quant Value FI
    311.42K0.40%

Stock Splits

  • Feb 20, 20191:6
  • Jun 4, 20181:12
  • May 30, 20121:6
  • Jul 27, 2004111:1